XML 24 R14.htm IDEA: XBRL DOCUMENT
v3.22.4

Goodwill and Other Intangible Assets | 3 Months Ended
--- | ---
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | 7. Goodwill and Other Intangible Assets There were no impairments of intangible assets during the three months ended September 30, 2022. During the three months ended September 30, 2021, the Company’s market capitalization significantly declined. As a result of the decline in market capitalization and qualitative and quantitative analysis the Company recognized an impairment of goodwill of $19.5 million. The following table provides the summary of the Company’s intangible assets as of September 30, 2022 and June 30, 2022, respectively. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2022
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted-
​ | ​ | Gross | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Net | ​ | Average
​ | ​ | Carrying | ​ | Accumulated | ​ | ​ | ​ | ​ | Carrying | ​ | Remaining
​ |  | Amount |  | Amortization |  | Impairment |  | Amount |  | Life (in years)
​ | ​ | (In thousands)
Definite-lived intangibles: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Acquired product technology rights | ​ | ​ | 45,400 | ​ | ​ | (8,471) | ​ | ​ | (3,224) | ​ | ​ | 33,705 |  | 12.04
Acquired technology right | ​ | ​ | 30,200 | ​ | ​ | (2,722) | ​ | ​ | — | ​ | ​ | 27,478 | ​ | 15.50
Acquired product distribution rights | ​ |  | 11,354 | ​ |  | (3,857) | ​ |  | (2,172) | ​ |  | 5,325 |  | 7.35
​ | ​ | ​ | 86,954 | ​ | ​ | (15,050) | ​ | ​ | (5,396) | ​ | ​ | 66,508 | ​ | 13.10
Indefinite-lived intangibles: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Acquired in-process R&D | ​ | ​ | 2,600 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,600 | ​ | Indefinite-lived
​ | ​ | ​ | 2,600 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,600 | ​ | ​
Total | ​ | $ | 89,554 | ​ | $ | (15,050) | ​ | $ | (5,396) | ​ | $ | 69,108 |  | 13.10
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, 2022
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted-
​ | ​ | Gross | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Net | ​ | Average
​ | ​ | Carrying | ​ | Accumulated | ​ | ​ | ​ | ​ | Carrying | ​ | Remaining
​ |  | Amount |  | Amortization |  | Impairment |  | Amount |  | Life (in years)
​ | ​ | (In thousands)
Definite-lived intangibles: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Acquired product technology rights | ​ | $ | 45,400 | ​ | $ | (7,667) | ​ | $ | (3,224) | ​ | $ | 34,509 |  | 12.33
Acquired technology right | ​ | ​ | 30,200 | ​ | ​ | (2,278) | ​ | ​ | — | ​ | ​ | 27,922 | ​ | 15.75
Acquired product distribution rights | ​ |  | 11,354 | ​ |  | (3,581) | ​ |  | (2,172) | ​ |  | 5,601 |  | 7.60
Other intangible assets | ​ | ​ | 4,666 | ​ | ​ | (3,004) | ​ | ​ | (1,662) | ​ | ​ | — | ​ | —
​ | ​ | ​ | 91,620 | ​ | ​ | (16,530) | ​ | ​ | (7,058) | ​ | ​ | 68,032 | ​ | 13.35
Indefinite-lived intangibles: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Acquired in-process R&D | ​ | ​ | 2,600 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,600 | ​ | Indefinite-lived
​ | ​ | ​ | 2,600 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,600 | ​ | ​
Total | ​ | $ | 94,220 | ​ | $ | (16,530) | ​ | $ | (7,058) | ​ | $ | 70,632 |  | 13.35
​ ​ ​ The following table summarizes the estimated future amortization expense to be recognized over the next five years and periods thereafter: ​
​ | ​ | ​ | ​
​ |  | September 30,
​ | ​ | (In thousands)
2023 (remaining 9 months) | ​ | $ | 4,563
2024 | ​ | ​ | 6,074
2025 | ​ | ​ | 5,934
2026 | ​ | ​ | 5,683
2027 | ​ | ​ | 5,652
2028 | ​ | ​ | 5,552
Thereafter | ​ | ​ | 33,050
Total future amortization expense | ​ | $ | 66,508
​ ​ Product Technology Rights The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Karbinal® ER. The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris for the exclusive rights to commercialize Karbinal® ER in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in August of 2033, with an optional initial 20-year extension. Poly-Vi-Flor and Tri-Vi-Flor. The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States. ADHD Portfolio. As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 17 years. Developed Technology Right TRRP Technology. As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of Neos’ core products and can potentially be used in future product development initiatives as well. Product Distribution Rights and Customer List In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. As of June 30, 2022, the customer list intangible asset was fully amortized. In-Process R&D IPR&D – NT0502. As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the in-process research and development will begin amortizing on a straight-line over the life of the product. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.5 million for the three months ended September 2022 and $2.1 million during the three months ended September 30, 2021, respectively.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration